Skip to main content
Premium Trial:

Request an Annual Quote

OncoVista Sells AdnaGen for up to $83M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OncoVista Innovative Therapies announced that it has sold its majority stake in tumor diagnostics subsidiary AdnaGen to an entity called Alere Holdings Bermuda Limited Canon's Court.

Under the terms of the deal, OncoVista, based in San Antonio, Texas, will receive an upfront payment of $10 million, milestone payments of up to $10 million related to certain financial goals being met within 24 months, and milestone payments of up to $63 million related to clinical, regulatory, and sales goals being met within 36 months.

OncoVista is receiving up to $65 million in cash as part of the deal, and said in a statement that it is entitled to receive its pro rata portion of about 78 percent of the entire $83 million offer.

OncoVista acquired AdnaGen in 2006, and owned about 78 percent of the Langenhagen, Germany-based firm.

AdnaGen is developing molecular diagnostic tests for breast, prostate, and colorectal cancers.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.